Trial Profile

Development of acid inhibition without hypergastrinemia

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 09 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pirenzepine (Primary) ; Vonoprazan (Primary)
Indications Duodenal cancer; Erosive oesophagitis; Gastric cancer; Gastro-oesophageal reflux; Helicobacter pylori infections; Peptic ulcer; Reflux oesophagitis
Focus Therapeutic Use

Most Recent Events

09 Jun 2021 New trial record
31 May 2021 Primary endpoint (Intragastric pH) has been met, according to Results published in the European Journal of Clinical Pharmacology.
31 May 2021 Results published in the European Journal of Clinical Pharmacology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com